First Tracks Biotherapeutics, Inc. cotiza a 34.05 USD y tiene una capitalización bursátil de $1.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Ro…
| Periodo | 2026-11 | 2026-08 | 2026-08 |
|---|---|---|---|
| Real | — | $-0.95 | — |
| Estimado | $-0.89 | $-0.80 | $-0.80 |
| Sorpresa | — | -18.7% | — |
| Métrica | TRAX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | — | -32.0% | — |
| Current Ratio | 10.20 | 2.84 | +7.36 |
| Debt / Equity | — | 0.28 | — |